Skip to content
Laxxon Medical

Laxxon Medical

Investor information

As of November 2026

Laxxon Medical Corp. is a privately held drug development company. With its SPID® platform, it develops its own pipeline of oral medicines, led by an oral GLP-1 RA, and partners with pharma companies, including on co-development projects.

At a glance

Focus: oral peptide delivery and innovative formulations enabled by the SPID® platform

LXM.2 is Laxxon's focus program: SPID®-printed oral GLP-1 RA microtablets in preclinical development, with Phase 1 planned for 2027 (press release of October 21, 2026).

Pipeline →

Company facts

Company
Laxxon Medical Corp., a privately held drug development company
Founded
2017
Headquarters
261 Madison Avenue, 9th Floor, New York, NY 10016, USA
Research and development
Laxxon Medical GmbH, Jena, Germany
Intellectual property
Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.
CEO and Chairman
Helmut Kerschbaumer

Ownership and funding

Ownership
Laxxon Medical Corp. is an independent, privately held company headquartered in New York. It is not a subsidiary of Xlife Sciences AG or of any other company, and Xlife Sciences AG holds no shares in Laxxon.
Funding
Since its founding in 2017, Laxxon has been financed by private and institutional investors.
Shareholder information
Shareholders receive a company update twice a year. Qualified investors can request company documents from investor relations.
Team
Around 40 employees.

Investor inquiries

Contact investor relations for company information and documents.

Contact us